相关实验视频
Updated: Jun 26, 2025

09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
2.7K
产后出血相关的血栓性微血管病变的特征和短期补充抑制的作用
Jessica K Kaufeld1, Lucas Kühne2,3, Ulf Schönermarck4
1Department of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany.
Kidney international reports
|May 20, 2024
概括
与怀孕相关的非典型血溶性尿素性综合征 (p-aHUS) 的治疗具有挑战性. 补充抑制可能有利于患者,但如果确定了血栓性微血管病变 (TMA) 的非遗传原因,治疗应是短期的,并停止.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血液学 血液学 血液学
- 产科 产科 产科 产科 产科
背景情况:
- 与怀孕相关的非典型血溶性尿素性综合征 (p-aHUS) 提出了独特的诊断和治疗挑战.
- 产后出血 (PPH) 或HELLP综合征等产周并发症可以驱动p-aHUS中的补体激活.
- 对p-aHUS的治疗建议很难从非怀孕的血栓性微血管病变 (TMA) 队列转移.
研究的目的:
- 在p-aHUS.中评估现实世界的诊断和治疗决策.
- 分析PPH对p-aHUS表现和结果的影响.
- 评估补充抑制在p-aHUS患者的疗效.
主要方法:
- 来自德国3家学术医院的40名p-aHUS患者的回顾性分析.
- 根据PPH的存在 (n=25) 或缺乏 (n=15) 患者的分层.
- 评估组织学TMA标志,遗传补充异常和治疗结果,包括替代疗法 (KRT) 和血交换 (PEX).
主要成果:
- 在84.2%的患者中存在组织学TMA迹象.
- 没有PPH的患者表现出病原性遗传补充异常的可能性更高 (20%vs0%).
- 补充抑制与一些PPH后皮层缩 (RCN) 患者的部分功能恢复有关,并且所有接受治疗的患者的功能恢复相似.
结论:
- 建议对p-aHUS采取有限的,短期的抗补疗法的务实方法.
- 如果出现TMA导致的除遗传补充异常之外的其他原因,应停止抗补充疗法.
- 补充抑制可能在与怀孕相关的TMA和p-aHUS中提供潜在的益处.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
681
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
681
Clot Retraction and Fibrinolysis
5.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.5K
Disorders of Hemostasis
845
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
845
Coagulation
6.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.2K
Extrinsic and Intrinsic Pathways of Hemostasis
7.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.2K
Introduction to Hemostasis
7.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.3K

